Silence Therapeutics: Zerlasiran showed durable reductions in lipoprotein

Silence Therapeutics announced positive topline results from the multiple dose component of the APOLLO phase 1 study of zerlasiran formerly SLN360 in 36 adults with baseline lipoprotein a , or Lp a , levels at or over 150 nmol/L and stable atherosclerotic cardiovascular disease ASCVD . Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp a , a key genetic risk factor for cardiovascular disease affecting approximately 20% of the world’s population…We are extremely pleased to see the excellent results we saw in healthy volunteers translate to our target population,” said Craig Tooman, President and CEO of Silence. “Zerlasiran delivered essentially complete Lp(a) knockdown on repeated dosing with greater durability than seen with single doses. The safety profile also continues to be very well suited for chronic use in a very large global population. We look forward to building on this dataset with the ongoing phase 2 study expected to readout in the first half of next year.”